Genetic Education for Prostate Cancer

(ENGAGE Trial)

This trial aims to determine whether a digital guide, a print guide, or usual care better assists prostate cancer survivors in learning about and requesting genetic testing for hereditary cancer risk. Researchers will divide participants into three groups, each receiving different educational materials and support for genetic testing. The study will examine how these methods influence decision-making and overall well-being. Men diagnosed with prostate cancer at least six months ago, who have not undergone genetic testing, and who can access the internet are ideal candidates for this trial. As an unphased trial, it offers participants the chance to contribute to valuable research that could enhance educational resources for prostate cancer survivors.

The trial information does not specify whether you need to stop taking your current medications. It seems focused on genetic education and testing, so it's unlikely that your medications will be affected.

Research has shown that digital guides for learning about genetics are generally safe and well-liked. In a review of 87 studies, 84% of patients using digital tools reported positive outcomes, such as better understanding and improved mental well-being. This indicates that the digital guide in this trial is likely safe and effective for participants.

For the print guide, no specific safety concerns have been mentioned. However, genetic testing and educational materials, like those in the print guide, are commonly used in medical practice and are usually well-tolerated. The National Comprehensive Cancer Network recommends these materials for patients with prostate cancer, providing some assurance of their safety.

Researchers are excited about the Genetic Education for Prostate Cancer trial because it explores innovative ways to educate patients about their genetic risk for cancer. Unlike traditional genetic counseling, the Digital Guide and Print+ arms provide comprehensive information through digital and print formats, making it more accessible and potentially less intimidating. These guides offer streamlined genetic testing options, allowing participants to understand their risks and make informed decisions more conveniently. By integrating videos, infographics, and real-time support, these new methods could enhance patient engagement and understanding, paving the way for more personalized cancer risk management.

Studies have shown that genetic testing can greatly assist prostate cancer patients by guiding treatment choices and clarifying family risk. This trial will compare various educational approaches to facilitate genetic testing. Participants in the Digital Guide Genetic Education Plus Streamlined Genetic Testing (DG+) arm will receive digital tools, which research indicates can enhance understanding and increase the likelihood of choosing genetic testing. Specifically, a review found that 84% of patients using digital tools reported improved knowledge and well-being. The Print Genetic Education plus Streamlined Genetic Testing (Print+) arm will offer print guides with detailed information about genetic risk and testing options, similar to traditional genetic counseling. Both digital and print methods aim to make genetic testing more accessible and understandable. The Enhanced Usual Care (EUC) arm will serve as a comparator, providing standard information and support.¹⁴⁶⁷⁸